(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Acurx Pharmaceuticals's earnings in 2026 is -$7,498,327.On average, 5 Wall Street analysts forecast ACXP's earnings for 2026 to be -$7,247,705, with the lowest ACXP earnings forecast at -$8,423,566, and the highest ACXP earnings forecast at -$4,602,877. On average, 5 Wall Street analysts forecast ACXP's earnings for 2027 to be -$7,744,524, with the lowest ACXP earnings forecast at -$10,529,458, and the highest ACXP earnings forecast at -$4,693,130.
In 2028, ACXP is forecast to generate -$8,855,059 in earnings, with the lowest earnings forecast at -$10,108,280 and the highest earnings forecast at -$7,400,705.